Blue Sail MedicalOn June 1st, in response on the investor interaction platform, the company stated that its glove business has undergone unprecedented and significant industry fluctuations since 2020. Currently, the company’s two major categories of gloves—nitrile gloves and PVC gloves—each have an annual production capacity of 25 billion units, operating at full capacity with full sales. Glove prices have also significantly increased compared to the end of 2025. The market supply and demand relationship has undergone a significant positive change, which is favorable to leading Chinese manufacturers, and historical inventory pressure has been significantly alleviated. The increase in inventory write-downs in 2025 was mainly due to two reasons. First, the company, based on the prudence principle of the Accounting Standards for Business Enterprises, regularly conducts impairment tests on inventories. Although prices have rebounded from their lowest point, there remains a difference between the historical cost and the net realizable value of some inventory items, necessitating the recognition of corresponding inventory write-downs based on accounting estimates. Second, in 2025, the company conducted reasonable impairment tests and scrapped certain fixed assets of the Health Protection Division, and the impairment losses from these assets were also reflected in the financial statements. These accounting treatments are normal measures for the company’s continuous optimization of its asset structure, aiming to more truthfully and fairly reflect the company’s asset status and operating results. From 2025 to date, the company has taken a series of substantive measures to improve the profitability of its glove segment, including introducing Thai industrial investors to address upstream energy shortages, implementing multiple technical improvements, and strategically locking in raw material costs through advance procurement. Currently, the company’s glove business costs have returned to a leading industry level, and it is foreseeable that the glove business will become the segment with the greatest performance recovery potential for the company in 2026.

Asahi KaseiThe released Q4 FY2026 report shows that the parent company’s net profit for the quarter was ¥38.186 billion, an increase of 4.56% year-on-year; total revenue was ¥813.242 billion, up 4.52% year-on-year. The company primarily engages in chemical-related businesses and has seven business divisions. The Chemical Division supplies petrochemical products, functional films, and functional resins. The Textile Division supplies synthetic textiles and nonwoven fabrics. The Housing Division engages in housing development and sales, renovation, and real estate transactions. The Building Materials Division supplies aerated lightweight concrete and high-performance thermal insulation materials. The Electronics Division manufactures and sells electronic materials and electronic components. The Pharmaceuticals and Medical Division supplies pharmaceuticals and medical devices, including artificial kidneys, blood purifiers, leukocyte removal filters, and virus removal filters. In addition, the company is involved in the design, construction, and maintenance of industrial facilities.

Recently, LyondellBasell has expanded its Purell product portfolio and further deepened its collaboration with healthcare customers. The Purell series of materials, specifically developed for the healthcare sector, is widely used in products such as syringes, ampoules, IV bottles, diagnostic device housings, laboratory ware, inhalers, and medical packaging.

Coveris and SABIC recently launched a collaborative project that successfully demonstrated the feasibility of a closed-loop recycling system for medical packaging. The project integrated the expertise of healthcare service providers, material manufacturers, and packaging manufacturers, proving that uncontaminated hospital plastic waste can be transformed into new, sensitive medical packaging. This project is dedicated to establishing a full-process circular system: medical packaging waste is uniformly collected and chemically recycled, then reintroduced into the medical industry supply chain, marking a significant step toward sustainable development in this highly regulated sector.

CLS CN, Feb 12 — No new stocks are available for subscription today. One new stock, Haisheng Medical, is listed on the Beijing Stock Exchange. New stocks listed today Haisheng Medical is a global provider of integrated medical devices for anesthesia and patient monitoring.The company's main business is the research and development, production, and sale of anesthesia and monitoring medical devices, with products widely used in terminal clinical needs in departments such as anesthesiology, ICU, and emergency medicine. The company's operating revenue for 2023-2025 is 306 million RMB, 304 million RMB, and 345 million RMB, respectively; the net profit is 78.04 million RMB, 70.92 million RMB, and 85.82 million RMB, respectively.

Junkosha is showcasing a range of new etched PTFE liner tubing products at MD&M West in Anaheim, California this week, designed to meet the evolving application demands of the peripheral vascular market. Among the new products, Junkosha has launched etched PTFE liner tubing with an inner diameter of up to 0.2 inches (5 mm), facilitating the research and development of large-bore device delivery systems.

On January 20, 2025, U.S. President Donald Trump signed an executive order announcing the United States' withdrawal from the World Health Organization (WHO). The United Nations received this notification on January 22 of the same year. According to the WHO Constitution, a member state can formally withdraw one year after submitting its withdrawal application. January 22nd of this year marks the one-year anniversary of the United States formally submitting its application to withdraw from the World Health Organization to the United Nations. According to the WHO Constitution, This means that the United States has procedurally and formally withdrawn from the World Health Organization.

Recently, the EU unveiled a draft for the Carbon Border Adjustment Mechanism (CBAM), expanding the tax scope from raw materials like steel and aluminum to downstream assembled products, including automotive parts (where steel and aluminum account for over 50%), home appliances (over 30%), and gardening tools (over 20%). The implementation will occur in three phases: starting from October 2023, a transition period for data reporting; in January 2025, the declaration will open; and by January 2026, full payment obligations will be implemented. The fees will be calculated as (emissions - free allowances) × carbon price - already paid costs. Sellers are advised to self-check their products, build green supply chains, and establish compliance databases.

According to Securities Star, as shown by the Tianyancha APP, Lepu Medical (300003.SZ) has made a new external investment, with the invested company being Lepu Biotechnology Co., Ltd. The legal representative is Pu Zhongjie, and the investment share is 13.17%. The company is engaged in pharmaceutical manufacturing and has a registered capital of 1,804,439,838 RMB. Currently, Lepu Medical has a total of 74 external investments.

An investor asked on the investor interaction platform: In the field of high-end polyether applications, emerging sectors such as new energy vehicles and photovoltaics have a strong demand for special polyethers, driving an annual growth rate of over 12% in demand for special polyethers. Moreover, the industry is increasing its R&D on low unsaturation polyethers, electronic-grade polyethers, and medical polyethers to meet the stringent requirements of the downstream, such as zero detection of harmful substances and compliance with bio-based content standards. Does the company have special polyethers used in photovoltaics, medical, and other fields? Longhua New Material (301149.SZ) stated on the investor interaction platform on December 4 that end amino polyether products can be used as curing agents for epoxy resins, decorative glue (hard glue) curing agents, wind turbine blade glue curing agents, polyamide hot melt adhesive, electronic sealing glue curing agents, electronic potting materials curing agents, electronic encapsulation materials curing agents, rapid curing RIM, construction structural glue curing agents, polyether amine modified curing agents, heavy-duty anti-corrosion coating curing agents, and curing agents for composite materials such as fishing rods, golf clubs, and tennis rackets. The company's polyether products can be applied in polyurethane fiberglass composite materials and in the photovoltaic frame sector. Currently, the technology is still being promoted, and specific application scenarios are determined by downstream customers based on their own needs.

On November 24, according to foreign media reports, Tesla CEO Elon Musk recently posted on social media that the company's AI5 chip is nearing the final design stage, and work has begun on the next-generation AI6 chip to be deployed in vehicles and data centers. The world's richest man stated, "Our goal is to achieve mass production of a new generation of AI chips every 12 months. The current onboard chip is the AI4 version, the AI5 is about to complete tape-out, and we have now initiated the development of AI6." In July this year, Samsung Electronics announced that it had secured a $16.5 billion contract to produce AI chips for Tesla. Musk revealed at the time that Samsung's new factory in Texas would be dedicated to the production of AI6 chips. "We expect the total number of chips produced will surpass that of all other AI chips combined," Musk emphasized, "This is no exaggeration."

On September 26, according to CCTV News, on September 25 local time, U.S. President Trump announced on his social media platform "Truth Social" that starting from October 1, the United States will implement a new round of high tariffs on various imported products. The measures include a 50% tariff on kitchen cabinets, bathroom sinks, and related building materials, a 30% tariff on imported furniture, and a 100% tariff on patented and branded drugs.

QichachaThe APP shows that recently,Shanghai Minwei Biotechnology Co., Ltd.Business changes occurred, additions were made.Guangxi Tencent Venture Capital Co., Ltd.To the shareholders, the registered capital will be increased to approximately 16.16 million yuan.QichachaThe information shows that the company was established in 2021, with Zhang Bingfeng as the legal representative. Its business scope includes technology development in the fields of biotechnology and medical technology, and its major shareholder is...Lepu MedicalPublic information shows that the company focuses on cutting-edge "multi-core macromolecular biopharmaceutical" innovation and platform development, aiming to create innovative drugs with global competitiveness.

A team from Linköping University in Sweden has developed artificial neurons made from conductive plastic, capable of simulating the advanced functions of biological neurons while exhibiting up to 17 key characteristics. The relevant findings were published in a recent issue of the journal "Science Advances." This breakthrough in artificial neurons opens up vast prospects for a new generation of implantable sensors, medical devices, and advanced robotics technology.

Toray announced that it officially began sales in the United States in July of a new catheter for the treatment of aortic valve stenosis. The company has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its “Inoue Balloon for Aortic Valve” catheter for balloon aortic valvuloplasty, and is marketing it in the U.S. under the name “INOUE BALLOON A.” Toray has been selling catheters for mitral valve stenosis in the United States for over 30 years, and this newly launched catheter is the company’s next product line following that. The Inoue Balloon for aortic valves has been sold in Japan since 2018, and has achieved a cumulative usage of over 10,000 units in medical institutions.

Apple Inc. announced on September 11 local time that its hypertension detection system for the smartwatch has been approved by the U.S. Food and Drug Administration and will be officially launched next week. This feature will be compatible with Apple Watch Series 9, Series 10, Series 11, Ultra 2, and Ultra 3 models.

Recently, Avantium announced that it has signed a capacity reservation agreement with BIOVOX, a pioneer in sustainable healthcare plastics. Under this agreement, BIOVOX commits to using Avantium's PEF (polyethylene furanoate) for various pharmaceutical applications. This PEF is expected to be produced in future industrial-scale facilities, and the multi-year capacity reservation ensures that BIOVOX has priority access to PEF produced in Avantium's future authorized network.As a supplier of medical-grade renewable polymers and compounds, BIOVOX has assessed the use of PEF in various pharmaceutical and medical applications. Compared to traditional petrochemical-based materials, pharmaceutical packaging based on PEF offers significant environmental benefits, aligning with the growing demand for sustainable solutions in the pharmaceutical industry.

On May 22nd, as the convoy of containers carrying the first batch of medical packaging products for export to Australia set off with a whistle, Haichang Medplas officially embarked on a new chapter of its internationalization strategy, achieving a "zero breakthrough" for Shanghai Pharmaceutical's pharmaceutical packaging materials in the mainstream international market. The smooth delivery of this first order to Australia marks the entry of Haichang Medplas' internationalization strategy into a substantive advancement phase. In the face of intense competition, Haichang Medplas has strategically positioned itself internationally with forward-looking vision and efficient execution. By successfully obtaining the U.S. FDA-DMF filing number in 2023, the company significantly enhances its international competitiveness, laying a solid foundation for Haichang Medplas to further expand into international markets.

According to the China Trade Remedy Public Information Network, on May 20, 2025, the United States International Trade Commission (ITC) voted to initiate a Section 337 investigation into certain balloon dilation devices, systems, and components. The investigation code is 337-TA-1449. The named respondents are: Fiagon GmbH, Hennigsdorf, Germany; Fiagon AG Medical Technologies, Hennigsdorf, Germany; Fiagon NA Corporation, Austin, Tex.; Fiagon NA, LLC, Austin, Tex.; Hemostasis, LLC, White Bear Lake, Minn.

Roche recently announced that it will invest $50 billion in the United States over the next five years. These investments further strengthen Roche's already significant footprint in the U.S., where it has 13 manufacturing and 15 research and development sites in the pharmaceutical and diagnostics sectors. It is expected to create over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 positions for the building and expansion of facilities.